REFERENCES
- Chang AY. Introduction to ifosfamide, carboplatin, etoposide chemotherapy. Semin Oncol 1995; 22 (suppl.7): 1-4.
- Chang AY, Asbury RF, Soros L, Garrow GC, HsieH J. Ifosfamide, carboplatin, etoposide chemotherapy in patients with metastatic non small cell lung cancer. Semin Oncol 1995; 22 (suppl. 7): 9-12.
- Von Zandwiik N, ten Bokkel Huinink WW, Wanders J et al. Dose finding studies with carboplatin, ifosfamide, etopo-side, and mesna in non small cell lung cancer. Semin Oncol 1990; 17 (suppl. 2): 16-19.
- Tepler I, Elias A, Young D et al. Use of recombinant human interleukin 3 (IL-3) after ICE chemotherapy for non small cell lung cancer (NSCLC): Effect on hematological recov-ery. Proc Am J Clin Oncol 1998; 11: 278, Abstr 990.
- Chang A, Mittleman A, Soros L et al. Phase I study of interleukin 6 (IL-6) in cancer patients treated with ifosfamide, carboplatin and etoposide (ICE). Blood 1992; 80 (suppl 1): 89 A, Abstr 345.
- Oken MM, Creech RM, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
- Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
- Crawford J, George M. The role of hematopoietic growth factors in support of ifosfamide, carboplatin, etoposide chemotherapy. Semin Oncol 1995; 22 (suppl.7): 18-22.
- Krigel RL, Palackdharry CS, Dadavic K et al. Ifosfamide, carboplatin, and etoposide plus granulocyte macrophage colony stimulating factor: a phase I study with apparent activi-ty in non small cell lung cancer. J Clin Oncol 1994; 12: 1251-1258.